Teresa Bitetti: Many of us have felt the impact of cancer, whether through personal experience or through the stories of those that we care about. 

At Takeda Oncology, our diverse team from around the globe is united by our aspiration to cure cancer. 

We are committed to ensuring that patients around the globe can access and benefit from our portfolio of medicines while advancing a pipeline of potential treatments for the future. 

P.K. Morrow: Our research and development efforts are focused on advancing treatments in three primary areas: thoracic cancers, gastrointestinal cancers, and hematologic cancers. 

And with that, we’ve built a portfolio of medicines that have reshaped the treatment landscape, and we’re committed to delivering new treatment options in areas of high unmet need by complementing our in-house expertise with a global network of collaborators. 

Teresa Bitetti: We see great value in advancing innovation from multiple sources and seek opportunities to partner with companies who share our aspiration to cure cancer. 

Our global footprint and broad capabilities allow us to enter a variety of unique partnerships which have resulted in important advances for patients. 

P.K. Morrow: At Takeda, we’re driven by an unwavering commitment to the patients whom we serve. 

Our approach is guided by our deep-rooted purpose to help those affected by cancer. 

Teresa Bitetti: We care about the patient and, at the end of the day, it’s our job to do everything we can to take the science that we understand to make sure that we deliver medicines to these patients and offer that hope of the aspiration that one day we will cure cancer.